Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 15 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-10.23 Insider Own37.22% Shs Outstand20.76M Perf Week20.75%
Market Cap179.99M Forward P/E- EPS next Y-5.52 Insider Trans3.07% Shs Float13.03M Perf Month10.17%
Income-112.90M PEG- EPS next Q-1.45 Inst Own45.80% Short Float6.26% Perf Quarter-26.09%
Sales0.00M P/S- EPS this Y50.66% Inst Trans2.89% Short Ratio2.31 Perf Half Y-1.20%
Book/sh8.78 P/B0.99 EPS next Y3.64% ROA-41.55% Short Interest0.82M Perf Year-57.91%
Cash/sh9.31 P/C0.93 EPS next 5Y- ROE-66.40% 52W Range6.38 - 29.70 Perf YTD15.17%
Dividend Est.- P/FCF- EPS past 5Y0.36% ROI-45.84% 52W High-70.81% Beta1.07
Dividend TTM- Quick Ratio9.24 Sales past 5Y-56.90% Gross Margin-249.44% 52W Low35.89% ATR (14)0.52
Dividend Ex-Date- Current Ratio9.24 EPS Y/Y TTM30.06% Oper. Margin0.00% RSI (14)67.17 Volatility7.90% 7.06%
Employees121 Debt/Eq0.41 Sales Y/Y TTM-100.00% Profit Margin- Recom1.29 Target Price32.00
Option/ShortYes / Yes LT Debt/Eq0.35 EPS Q/Q48.07% Payout- Rel Volume1.11 Prev Close7.91
Sales Surprise-100.00% EPS Surprise-6.81% Sales Q/Q-100.00% EarningsMay 09 AMC Avg Volume352.61K Price8.67
SMA2020.89% SMA509.00% SMA200-21.84% Trades Volume391,941 Change9.61%
Date Action Analyst Rating Change Price Target Change
Jun-25-24Initiated Oppenheimer Outperform $25
Apr-30-24Initiated H.C. Wainwright Buy $30
Jul-07-22Upgrade Truist Hold → Buy $4
Jul-23-21Downgrade Cantor Fitzgerald Overweight → Neutral
May-03-21Downgrade SVB Leerink Outperform → Mkt Perform $5
Apr-29-21Downgrade Truist Buy → Hold $30 → $9
Apr-29-21Downgrade RBC Capital Mkts Outperform → Sector Perform $6
Apr-29-21Downgrade Chardan Capital Markets Buy → Neutral $5
Dec-16-20Initiated UBS Neutral $13
Nov-12-20Upgrade Raymond James Underperform → Mkt Perform
Jul-10-24 08:00AM
Jun-18-24 08:00AM
Jun-11-24 08:00AM
May-10-24 03:36PM
09:35AM Loading…
May-09-24 11:55PM
May-03-24 08:00AM
May-02-24 10:01AM
Apr-30-24 07:39AM
Apr-29-24 08:33AM
Apr-25-24 04:05PM
Apr-23-24 09:40AM
09:35AM Loading…
Apr-19-24 09:35AM
Apr-04-24 09:40AM
Apr-03-24 09:35AM
Mar-27-24 09:35AM
Mar-21-24 07:52AM
Mar-20-24 05:33AM
Mar-19-24 09:40AM
Mar-18-24 10:53PM
Mar-06-24 03:07PM
Feb-28-24 04:05PM
Feb-27-24 06:10AM
Feb-22-24 06:15AM
08:00AM Loading…
Feb-12-24 08:00AM
Feb-08-24 07:00AM
Feb-05-24 07:45AM
Feb-01-24 05:30PM
Jan-29-24 08:00AM
Jan-04-24 08:27AM
Dec-07-23 04:05PM
Nov-28-23 04:05PM
Nov-09-23 04:51PM
Nov-06-23 08:00AM
Nov-04-23 05:54PM
Oct-24-23 12:30PM
Sep-26-23 04:05PM
Sep-21-23 04:05PM
Sep-05-23 04:05PM
Aug-21-23 04:05PM
Aug-14-23 08:00AM
Aug-10-23 04:20PM
Jun-12-23 08:00AM
Jun-02-23 08:00AM
May-25-23 06:30AM
May-18-23 09:00AM
May-11-23 04:47PM
May-10-23 04:05PM
May-02-23 04:30PM
Apr-23-23 01:00PM
Apr-21-23 06:03AM
Apr-18-23 08:00AM
Apr-17-23 04:05PM
Apr-04-23 09:40AM
Mar-30-23 04:05PM
Mar-02-23 10:23AM
Feb-27-23 04:05PM
Jan-18-23 04:05PM
Dec-06-22 04:05PM
Nov-10-22 04:05PM
Nov-04-22 12:08PM
Oct-27-22 04:05PM
Sep-30-22 04:45PM
Sep-27-22 04:05PM
Sep-23-22 04:05PM
Sep-15-22 05:19PM
Sep-14-22 08:00AM
Sep-08-22 04:05PM
Aug-26-22 04:05PM
Aug-11-22 04:05PM
Aug-10-22 04:05PM
Aug-01-22 04:05PM
Jul-25-22 07:16AM
Jul-15-22 09:52AM
Jul-08-22 08:00AM
Jul-07-22 05:14PM
Jul-06-22 04:05PM
Jun-24-22 08:00AM
Jun-09-22 08:00AM
Jun-02-22 04:05PM
May-19-22 08:00AM
May-18-22 08:11AM
May-17-22 04:05PM
May-12-22 04:05PM
Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company that engages in the development of gene therapies for ocular and rare diseases. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer, and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Lupher, Jr. Mark L.DirectorFeb 07 '24Buy1.35130,000175,500130,000Feb 09 05:50 PM
Scopa James PaulDirectorFeb 07 '24Buy1.35100,000135,000100,000Feb 09 05:51 PM
Seyedkazemi SetarehChief Development OfficerSep 15 '23Sale1.526,2019,42947,674Sep 18 06:54 PM